Leukemia patient gets emergency drug sent from US

October 23, 2006 15:48


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user uxperience almost completely free of ads
  • Access to our Premium Section and our monthly magazine to learn Hebrew, Ivrit
  • Content from the award-winning Jerusalem Repor
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

A boy suffering from T-cell acute lymphoblastic leukemia will now be able to undergo a bone marrow transplant at Sheba Medical Center after the GlaxoSmithKline pharmaceutical company flew over a drug as yet unavailable in Israel. The drug, called Arranon (Nelarabine), is registered in the US but not yet by the Health Ministry. When the Israeli branch of the company heard of the case, he agreed to have the drug supplied to the child free, and also not to charge for the transportation expenses over the weekend. His condition after two treatments has improved "significantly," according to Dr. Amos Toren, the Sheba pediatric oncologist who is treating him and will soon perform the bone marrow transplant. "We continue to hope that he will be cured."

Related Content

[illustrative photo]
September 24, 2011
Diabetes may significantly increase risk of dementia